Citadel Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Citadel Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,290	Closed	-$80.6K	–	14458
2023 Q1	$80.6K	Sell	9,290 -3,150	-25%	-$39.7K	﹤0.01%	11546
2022 Q4	$163K	Buy	12,440 +305	+3%	+$3.61K	﹤0.01%	10474
2022 Q3	$209K	Buy	12,135 +110	+0.9%	+$1.89K	﹤0.01%	10317
2022 Q2	$132K	Buy	12,025 +4,875	+68%	+$69.8K	﹤0.01%	11107
2022 Q1	$159K	Sell	7,150 -2,590	-27%	-$62.4K	﹤0.01%	11787
2021 Q4	$335K	Buy	9,740 +1,875	+24%	+$88.6K	﹤0.01%	10681
2021 Q3	$483K	Buy	7,865 +4,800	+157%	+$314K	﹤0.01%	9954
2021 Q2	$239K	Buy	3,065 +2,045	+200%	+$128K	﹤0.01%	11783
2021 Q1	$57K	Buy	+1,020	New	+$76.6K	﹤0.01%	12837
2020 Q4	–	Sell	-590	Closed	-$72K	–	10988
2020 Q3	$72K	Buy	+590	New	+$67.5K	﹤0.01%	9450

Other funds holding CYCN

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's CYCN Position: Q2 2026 in Review

Citadel Advisors increased its Cyclerion Therapeutics (CYCN) stake by 227% in Q2 2026, buying an estimated $135K and bringing the position to 59,795 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #12043.

Citadel Advisors first reported a position in CYCN in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.42M in Q2 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

Citadel Advisors held 59,795 shares of Cyclerion Therapeutics worth $203K as of Q2 2026.
Citadel Advisors bought 41,534 Cyclerion Therapeutics shares in Q2 2026, an estimated $135K.
Cyclerion Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12043 holding.
Citadel Advisors first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 9 quarters since.
Citadel Advisors's Cyclerion Therapeutics position peaked at $3.42M in Q2 2019.
21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.